Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novavax sees weak Covid vaccine sales
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals and a pipeline of new vaccines it's now evaluating for R&D.
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
(Reuters) -
Novavax
cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its
COVID
-19
vaccine
, ahead of handing over the rights to sell the shot to French drugmaker Sanofi. Shares of the U.S. biotech firm fell 3% to $8.73.
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Novavax
has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its
Covid
-19 and influenza combination
vaccine
(CIC) and standalone influenza vaccines after a month-long clinical hold. The FDA initially ...
FDA removes clinical hold on Novavax’s COVID-19-influenza combo vaccine
The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.
FDA lifts clinical hold on Novavax's combo COVID-flu shot
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after identifying a safety concern.
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?
On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health and Social Care, signed a Termination and Settlement Agreement and an amendment to resolve disputes over their updated COVID-19 vaccine supply contract from July 1,
Hosted on MSN
1d
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
Novavax
(NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its ...
Business Insider
13h
Novavax Advances Vaccine Strategy Amid Financial Shifts
In its recent third-quarter 2024 earnings report,
Novavax
highlighted significant advancements in its
vaccine
portfolio, including the removal of a clinical hold by the U.S. FDA on its ...
FiercePharma
7d
Novavax coughs up $123.8M to settle COVID vaccine supply dispute with UK
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
AOL
1d
Novavax: Stock plunges after quarterly earnings, but sees hope in licensing deals
Novavax
's
COVID
-19
vaccine
continues to be its only commercial product and currently has about 2%-3% market share, ...
16h
Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback